who added that the new vaccine also seems to achieve a more durable response than Moderna's first bivalent shot mRNA-1273.211, based on the original SARS-CoV-2 and the Beta variant. With Omicron ...

Moderna has reported preliminary clinical results with a bivalent version of its COVID-19 vaccine that combines its original version with another targeting the Beta variant, and seems to offer ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the fall and winter seasons. Here we answer common questions about the latest ...

Since their introduction last year, researchers have been monitoring the real-world impact of the new respiratory syncytial ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

FILE: Pfizer, left, and Moderna bivalent COVID-19 vaccines are readied for use at a clinic, Nov. 17, 2022, in Richmond, Va. The latest COVID-19 wave of infections across South Florida and the ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus, or RSV, in adults 60 years and older, making it the country's first authorized mRNA-based ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

The number of COVID cases increased last week to 146. Cases had been falling in April and May and were as low as 31 at the ...

Moderna's Stéphane Bancel is stepping down from his role as chief commercial officer, a significant shift for the company as it approaches the rollout of several new vaccines. Source: Pixabay.